SCHEMBL2860871

SCHEMBL2860871

[NH]C(Cc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
TDP1 Q9NUW8 2/20 0.52
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KMT2A Q03164 1/20 0.52
CTRB1 P17538 2/20 0.50
LTA4H P09960 1/20 0.49
LAP3 P28838 1/20 0.49
SRR Q9GZT4 2/20 0.49
LMNA P02545 1/20 0.47
HCAR2 Q8TDS4 1/20 0.47
CYP1A2 P05177 1/20 0.47
CTSB P07858 2/20 0.47
SLC15A1 P46059 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2581152 0.84 ALDH1A1 (0.49) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL8892531 0.84 MMP8 (0.58) ALDH1A1L3MBTL1KMT2ASRRLMNA
SCHEMBL8939122 0.81 ATM (0.53) ALDH1A1L3MBTL1KMT2ASRRLMNA
SCHEMBL1555297 0.81 ALDH1A1 (0.57) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL4219709 0.79 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL7298214 0.79 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL262278 0.79 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL4326937 0.79 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL21811160 0.79 CYP1A2 (0.59) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL8392561 0.79 ALDH1A1 (0.60) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2080779-B1 POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST NIPPON KAYAKU KK (JP) 2016-05-18 EP claimed
US-8334364-B2 High-molecular weight derivative of nucleic acid antimetabolite NIPON KAYAKU KABUSHIKI KAISHA (JP) 2012-12-18 US claimed
EP-1881020-B1 POLYMERIC DERIVATIVE OF CYTIDINE METABOLIC ANTAGONIST NIPPON KAYAKU KK (JP) 2010-08-11 EP claimed
US-7700709-B2 Polymeric derivative of cytidine metabolic antagonist NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2010-04-20 US claimed
US-20090281300-A1 HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-11-12 US claimed
EP-2080779-A1 POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST Nippon Kayaku Kabushiki Kaisha (JP) 2009-07-22 EP claimed
US-20090012252-A1 Polymeric Derivative of Cytidine Metabolic Antagonist NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-01-08 US claimed
EP-1881020-A1 POLYMERIC DERIVATIVE OF CYTIDINE METABOLIC ANTAGONIST Nippon Kayaku Kabushiki Kaisha (JP) 2008-01-23 EP claimed
EP-2080779-B1 POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST NIPPON KAYAKU KK (JP) 2016-05-18 EP disclosed
US-8334364-B2 High-molecular weight derivative of nucleic acid antimetabolite NIPON KAYAKU KABUSHIKI KAISHA (JP) 2012-12-18 US disclosed
EP-1881020-B1 POLYMERIC DERIVATIVE OF CYTIDINE METABOLIC ANTAGONIST NIPPON KAYAKU KK (JP) 2010-08-11 EP disclosed
US-7700709-B2 Polymeric derivative of cytidine metabolic antagonist NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2010-04-20 US disclosed
US-20090281300-A1 HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-11-12 US disclosed
EP-2080779-A1 POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST Nippon Kayaku Kabushiki Kaisha (JP) 2009-07-22 EP disclosed
US-20090012252-A1 Polymeric Derivative of Cytidine Metabolic Antagonist NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-01-08 US disclosed
EP-1881020-A1 POLYMERIC DERIVATIVE OF CYTIDINE METABOLIC ANTAGONIST Nippon Kayaku Kabushiki Kaisha (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281300-A1 HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE POLRMT, POLN, POLI ALDH1A1 1934/4885TDP1 224/4885MAPK1 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.